Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1 2Phase EARLY_PHASE1 1Phase 1/2 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Head & Neck 1Gynecologic 1Breast 1

Conditions

Prostatic Neoplasms 2Neoplasms 1

Interventions

pembrolizumab 93Nivolumab 61Docetaxel 55Cyclophosphamide 49enzalutamide 44Magnetic Resonance Spectroscopy 33Ipilimumab 33Gemcitabine 32Abiraterone Acetate 30Prednisone 29fludarabine 28Everolimus 27Paclitaxel 25Cisplatin 24Radiotherapy 23Carboplatin 23Sunitinib 22cabozantinib 21atezolizumab 20Radiosurgery 20Specimen Handling 19Sorafenib 18Bevacizumab 18pazopanib 17bicalutamide 17abiraterone 17Biopsy 15temsirolimus 14darolutamide 14apalutamide 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Genistein × Genitourinary × Clear all
NCT00005827 2012-04-24

Genistein in Treating Patients With Stage II, Stage III, or Stage IV Prostate Cancer

UNC Lineberger Comprehensive Cancer Center

Phase 1 Withdrawn
Genitourinary

Prostatic Neoplasms

NCT00001696 2008-03-04

A Pharmacokinetic Study of Genistein, a Tyrosine Kinase Inhibitor

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
15 enrolled
Genitourinary

Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡